This Latvian Scientist Says His Startup Is Winning The AI Drug Discovery Race

Insilico Medicine, backed by blue-chip investors like Warburg Pincus and Qiming Venture Partners, has 17 preclinical drug candidates so far and earlier this month signed a $500 million licensing deal with Italy’s Menarini.

Related Keywords

Moscow ,Moskva ,Russia ,China ,Italy ,Singapore ,Latvia ,Hong Kong ,Qiming ,Sichuan ,Italian ,Chinese ,Latvian ,Warburg Pincus ,Alex Zhavoronkov ,Massimiliana Landini Aleotti ,Elcin Barker Ergun ,Bloomberg ,Johns Hopkins University ,Menarini Group ,Moscow State University ,Temasek ,New York Based Insilico Medicine ,Qiming Venture ,Moscow State ,Stemline Therapeutics ,Barker Ergun ,Nasdaq Listed Exelixis ,Qiming Venture Partners ,Wuxi Apptec ,Pavilion Capital ,Insilico Medicine ,Xtalpi ,Ai Drug Discovery ,Ai Startups ,Ai Drug Discovery Startup ,Insilico Ipo ,Xtalpi Ipo ,Pharma Ai ,Nai Drug ,Generative Ai ,